Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Non-Current Deffered Revenue: 2021-2024

Historic Non-Current Deffered Revenue for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $244.6 million.

  • Autolus Therapeutics' Non-Current Deffered Revenue rose 10.92% to $253.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $253.4 million, marking a year-over-year increase of 10.92%. This contributed to the annual value of $244.6 million for FY2024, which is 43.13% up from last year.
  • Per Autolus Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $244.6 million for FY2024, which was up 43.13% from $170.9 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Non-Current Deffered Revenue ranged from a high of $244.6 million in FY2024 and a low of $47.0 million during FY2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $170.9 million (2023), whereas its average is $180.5 million.
  • Data for Autolus Therapeutics' Non-Current Deffered Revenue shows a peak YoY skyrocketed of 167.78% (in 2022) over the last 5 years.
  • Over the past 4 years, Autolus Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $47.0 million in 2021, then spiked by 167.78% to $125.9 million in 2022, then surged by 35.74% to $170.9 million in 2023, then spiked by 43.13% to $244.6 million in 2024.